Preliminary Program

Preliminary Program

We are planning an amazing program for you. Stay tuned…

We are planning an amazing and innovative program for ATTD 2020.

See below a list of speakers and the topics of their state-of-the-art lectures

*Updated as of 14 July, 2019

NameLast NameCountryTopics
StephanieAmielUKDebate on SGLT2 for type 1 diabetes – Pro:  Thomas Danne. Con: Stephanie Amiel
KatharineBarnardUKOnboarding and support needs for people with diabetes (PWD) and health care providers (HCPs)
RoyBeckUSATime in range and diabetes complications
RichardBergenstalUSAWhy is there a resurgence in diabetes complications and what can we do about it?
BruceBodeUSA·         Use of decision support systems in the hospital to manage glucose

·         Ultra fast-acting insulins in closed-loop systems

CharlotteBoughtonUKTraining and patient selection for the artificial pancreas
NatašaBratinaSloveniaClosed-loop in school
MarcBretonUSAClinical trial results of an artificial pancreas (AP) System that anticipates physical activity atterns in Type 1 diabetes
RoqueCardona-HernandezSpainUnmet technological needs in minority people in Europe
AntonioCerielloSpainGlucose variability as a risk factor for complications in diabetes
PratikChoudharyUKUsing neuroimaging to understand mechanisms of hypoglycemia unawareness
AmyCriegoUSAContinuous glucose monitoring (CGM) as initial diabetes technology
ThomasDanneGermany·         Debate on SGLT2 for T1D:  Pro: Thomas Danne Con: Stephanie Amiel

·         Experience with risk mitigation using SGLT-inhibitors in type 1 diabetes

EyalDassauUSAFirst clinical report of on-body artificial pancreas in pediatric and outpatient extended use of a mobile app
AsmaDeebUAEUnmet technology needs in Arabic region, Africa and Asia
ThomasDejgaardDenmarkGLP-1 and DPP-IV in type 1 diabetes
KlemenDovcSloveniaClosed-loop and physical activity
FrancisDoyle IIIUSAAutomated adaptive control in the outpatient setting – Interim results of the iDCL Harvard study
MetteDue-ChristiansenUKPsychological issues at diagnosis of type 1 diabetes
StevenEdelmanUSAAfrezza – How to use it and when
GregoryForlenzaUSAClinical Implementation and utilization of hybrid closed loop (HCL) technology
GuidoFreckmannGermanyWhich standards do we need for continuous glucose monitoring (CGM)?
SatishGargUSASGLT inhibitors for type 1 diabetes – Introduction
PeterGottliebUSAMethyldopa for early intervention in Type 1 diabetes
LutzHeinemannGermanyDiabetes technology and trash
SimonHellerUKUnderstanding the impact of hypoglycaemia: Severe, non-severe and sensor detected hypoglycemia
IrlHirschUSA·         Who will use SMBG in five years from now?

·         A Real-World Look of time in range (TIR) and glucose management indicator (GMI)

RomanHovorkaUKA new closed loop system from Cambridge: CamAPS-FX
PeterJacobsUSAUsing machine learning to predict glucose changes during aerobic, anaerobic and mixed forms of exercise in patients with type 1 diabetes
ParthaKarUKEngaging healthcare stakeholders for improving access to modern technologies via social media
DavidKlonoffUSAReal-World evidence in clinical trials
OlgaKordonouriGermanyKilling two birds with one stone: should diabetes screening be combined?
BorisKovatchevUSA·         Biosensing, diabetes data science and decision support

·         Latest artificial pancreas (AP) developments

LoriLaffelUSAApproaches to increasing glucose time-in-range in the pediatric age group
NebojsaLalicSerbiaInsulin pump treatment and insulin sensitivity during pregnancy: gestational vs. pre-existing diabetes
DavidMaahsUSAUnmet technology needs in pediatric diabetes – conclusions
ChantalMathieuBelgiumSGLT2 in type 1 diabetes – efficacy
LaurelMesserUSASkin in the game: Preserving skin integrity for sustained device use
HelenMurphyUKThe use of automated insulin delivery (AID) in type 1 diabetes Pregnancy
KirstenNørgaardDenmarkFiAsp Insulin – evidence and experience in using it
MoshePhillipIsraelDigital diabetes
WalterPoriesUSALong-term outcome of metabolic surgery
FransPouwerDenmarkImpact of hypoglycemia on patient reported outcomes
ClaireReidyUKSocial Media – structured peer support – benefits and pitfalls
MarianRewersUSAGeneral population screening for type 1 diabetes
MichaelRiddellCanadaPhysiologic and technologic challenges of exercise management in diabetes
AndreaScaramuzzaItalyUnmet technology needs in pediatric diabetes – Introduction
EyalSheinerIsraelMaternal and neonatal long-term outcome after pregnancy complicated with diabetes
JenniferSherrUSAAdjunctive Therapies for type 1 diabetes – Pramlintide and DPP-IV
JaySkylerUSA·         The Evolution of diabetes technology

·         Towards the cure of type 1 diabetes

FrankSnoekthe NetherlandsFear of hypoglycemia
StuartWeinzimerUSA·         Human factor in closed-loop

·         The role of Subcutaneous Glucagon

YarivYogevIsraelControversies in the treatment of diabetes in pregnancy- how to define well controlled?